Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome not adequately controlled by Somatostatin Analog (SSA) Therapy

Trial Profile

A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome not adequately controlled by Somatostatin Analog (SSA) Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2019

At a glance

  • Drugs Telotristat etiprate (Primary)
  • Indications Malignant carcinoid syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TELESTAR
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 19 Jan 2019 Results assessing the patient-reported outcomes, presented at the 2019 Gastrointestinal Cancers Symposium
    • 23 Nov 2018 Results of an exploratory, post hoc analyses to understand the relationship between symptoms and health-related Quality-of-Life benefits using data from TELESTAR trial published in the Clinical Therapeutics
    • 16 Oct 2018 According to an Ipsen media release, based on the positive results of the TELESTAR and TELECAST trials, the Health Canada approved XERMELO (telotristat ethyl) for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue therapy, in patients inadequately controlled by SSA therapy alone.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top